Treatment of alcoholism and depression and/or dysphoric mood using ibudilast

A technology of ibudilast, depression, applied in the field of treatment of alcoholism and depression and/or anxiety using ibudilast

Inactive Publication Date: 2019-03-15
MEDICINOVA INC
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although drugs such as acamprosate (CAMPRAL), ondansetron (ZOFRAN), naltrexone (VIVITROL), disulfiram (ANTABUSE), and calcium citratecyanamide are used as therapeutic agents for the treatment of alcoholism , but these therapeutic agents have drawbacks related to their efficacy and associated side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of alcoholism and depression and/or dysphoric mood using ibudilast
  • Treatment of alcoholism and depression and/or dysphoric mood using ibudilast
  • Treatment of alcoholism and depression and/or dysphoric mood using ibudilast

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Example 1. Evaluation of ibudilast as a therapeutic agent for reducing spontaneous alcohol consumption in mice

Embodiment 1-A

[0055]The ability of ibudilast (MN-166) to reduce spontaneous alcohol consumption was examined under blinded conditions in selectively bred alcohol-preferring (P) rats and heavy drinking (HAD1) rats, as well as in a mouse model of alcohol dependence . Although each model is characterized by elevated alcohol intake, drugs such as quetiapine and levetiracetam do not selectively reduce alcohol consumption in these models.

[0056] For the study, adult male P rats and HAD1 rats were randomly assigned to receive one of four doses of ibudilast - 0 mg / Kg, 3 mg / Kg, 6 mg / Kg or 9 mg / Kg, where Eight rats were assigned to each dose. Each dosing group was balanced to an average 2 hours / day alcohol (15% v / v) intake. Rats had simultaneous access to water and Mazola corn oil was used as vehicle.

[0057] The study was divided into four pilot phases. During the maintenance test phase, rats in the treatment groups were subcutaneously injected with ibudilast ( 2 mL / kg s.c.), and 8 hours lat...

Embodiment 1-B

[0063] In a separate study, adult male C57BL / 6J mice were used to evaluate ibudilast as a therapeutic agent for the treatment of alcohol dependence. Two groups of mice were used for this study. Mice in the first group were trained to drink alcohol (alcohol-dependent (EtOH) mice) using a 2 h / day free-choice (15% v / v alcohol) drinking program, while mice in the second group were given water and Mice served as control (alcohol independent (CTL)). Both alcohol-dependent and alcohol-independent groups had the same number of mice (N=37-38 / group).

[0064] Mice in the alcohol-dependent group were then exposed to chronic intermittent alcohol (CIE) vapors for 16 hours / day for 4 days. After a 72-h enforced withdrawal period, alcohol-dependent mice were again allowed access to alcohol for 2 h per day for 5 consecutive test days. This pattern of 4 consecutive days of chronic intermittent alcohol vapor exposure followed by mandatory abstinence and a 5-day alcohol acquisition trial perio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Alcoholism, and symptoms and negative effects thereof may be treated using ibudilast or a pharmaceutically acceptable salt thereof. Patients diagnosed with alcohol use disorder and who exhibit symptoms of depression and / or dysphoric mood can be treated using ibudilast or a pharmaceutically acceptable salt thereof.

Description

Background technique [0001] This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 62 / 333,990, filed May 10, 2016, the contents of which are hereby incorporated by reference in their entirety. [0002] Excessive alcohol intake is a major global health problem. Alcoholism is considered a symptom of chronic disease, drug addiction, a learned response to crisis, an underlying psychological or physical disorder, or a combination of these factors, and is recurrent in spite of substantial negative, physical, and psychosocial effects Use alcohol as a sign. [0003] Most approaches to treating alcohol use disorder (AUD) require the alcoholic to recognize his or her disorder and abstain from alcohol. Treatment options may include a combination of psychological rehabilitation, organized self-help groups, behavior modification-based aversion therapy, injectable vitamins or hormones, and use of abstinence maintenance medications. [0004] Many pati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/44A61K31/4439
CPCA61K45/06A61K31/485A61P25/32A61P25/24A61K31/437A61K31/135A61K31/185A61K31/197A61K31/265A61K31/357A61K31/4015A61K31/4178A61K31/4985A61K31/517A61K31/554A61K2300/00A61K9/0053
Inventor 岩城裕一
Owner MEDICINOVA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products